INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

INMB Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

INmune Bio, Inc.NASDAQ: INMB

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $3.77M, compared with -$7K a year earlier. Trailing-twelve-month accounts receivables was $646K. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Accounts receivables amounted to 6264.0% of revenue in FY2025, down 1114.6 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $3.77M or moves back toward the trailing-twelve-month quarterly average of $161.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.77M+281.6% QoQ
Last fiscal yearDec 2025
-$3.13M-403.2% YoY
LTMMar 2026
$646K-49.3% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+53971.4%——
1 year-403.2%——
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(3.13M) USD
Year-over-year change
-403.2%

Accounts Receivables vs competitors

How INMB compares with its peers on the latest reported figures

  • INMB's LTM Mar 2026 accounts receivables of $646K is the largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -49.3% is the highest of 2, against a peer median of -207.8%.
INMB Competitors Peer median
Accounts Receivables for INMB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INMBINmune Bio, Inc.LTM Mar 2026$646K -49.3%+1.9%—
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$605K -207.8%—6.7%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$0 ———
PDSBPDS Biotechnology CorporationLTM Mar 2026$0 ———
Peer median (excluding INMB) $0-207.8%—6.7%

Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Depreciation & Amortization000084K
Deferred Income Tax00000
Stock-Based Compensation4.8M7.15M7.37M7.61M9.91M
Change in Working Capital(3.09M)(2.86M)10.44M1.04M(2.53M)
Accounts Receivables(3.71M)(2.96M)6.02M1.03M(3.13M)
Inventory3.71M2.96M000
Accounts Payables2.26M1.4M2.72M(1.37M)1.86M
Other Working Capital(5.35M)(4.27M)1.7M1.38M(1.25M)
Other Non-Cash Items126K328K224K79K15.89M
Operating Cash Flow(28.5M)(22.69M)(11.98M)(33.36M)(22.58M)
Capital Expenditures(15M)000(1.04M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(15M)000(1.04M)
Debt Repayment14.95M0(5M)(10M)0
Common Stock Issued80.25M699K775K27.79M27.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.15M30K0422K0
Financing Cash Flow96.36M729K(4.23M)18.21M27.61M
Effect of Forex Changes(10K)(700K)(100K)224K(159K)
Net Change in Cash52.84M(22.66M)(16.31M)(14.93M)3.83M
Free Cash Flow(43.5M)(22.69M)(11.98M)(33.36M)(23.62M)

INmune Bio, Inc.

NASDAQ:INMB

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.